- Home
- QCLS vs BOLT Comparison
QCLS vs BOLT Comparison
Compare QCLS & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCLS
- BOLT
- Stock Information
- Founded
- QCLS 2014
- BOLT 2015
- Country
- QCLS United States
- BOLT United States
- Employees
- QCLS N/A
- BOLT N/A
- Industry
- QCLS Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- QCLS Health Care
- BOLT Health Care
- Exchange
- QCLS Nasdaq
- BOLT Nasdaq
- Market Cap
- QCLS 12.5M
- BOLT 11.5M
- IPO Year
- QCLS N/A
- BOLT 2021
- Fundamental
- Price
- QCLS $3.80
- BOLT $5.86
- Analyst Decision
- QCLS
- BOLT Buy
- Analyst Count
- QCLS 0
- BOLT 4
- Target Price
- QCLS N/A
- BOLT $34.00
- AVG Volume (30 Days)
- QCLS 1.3M
- BOLT 37.7K
- Earning Date
- QCLS 11-13-2025
- BOLT 11-14-2025
- Dividend Yield
- QCLS N/A
- BOLT N/A
- EPS Growth
- QCLS N/A
- BOLT N/A
- EPS
- QCLS N/A
- BOLT N/A
- Revenue
- QCLS N/A
- BOLT $4,167,000.00
- Revenue This Year
- QCLS N/A
- BOLT N/A
- Revenue Next Year
- QCLS N/A
- BOLT N/A
- P/E Ratio
- QCLS N/A
- BOLT N/A
- Revenue Growth
- QCLS N/A
- BOLT N/A
- 52 Week Low
- QCLS $3.24
- BOLT $4.59
- 52 Week High
- QCLS $174.27
- BOLT $13.80
- Technical
- Relative Strength Index (RSI)
- QCLS N/A
- BOLT 52.16
- Support Level
- QCLS N/A
- BOLT $5.65
- Resistance Level
- QCLS N/A
- BOLT $6.35
- Average True Range (ATR)
- QCLS 0.00
- BOLT 0.33
- MACD
- QCLS 0.00
- BOLT -0.02
- Stochastic Oscillator
- QCLS 0.00
- BOLT 35.21
About QCLS Q/C Technologies Inc. Common Stock
Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.